OmbuMed is a telehealth technology company whose website positions it as “bringing the doctor’s office into the home.” Its core product, OmbuHome, is designed to give physicians real-time clinical data during remote consultations, rather than relying solely on video communication. The goal is to narrow the gap between a standard video visit and an in-person clinical examination. The company was founded in 2019, discloses offices in Utah, Buenos Aires, and Barcelona, and established a strategic partnership with Latin American manufacturer Mirgor in 2023.
Based on the information disclosed, OmbuMed is best understood as a combined “hardware device + telehealth workflow” solution. The device supports remote clinical examinations, covering cardiac activity detection, abdominal/chest/cardiac auscultation, lung sound checks, detection of ear canal infections or issues, blood oxygen monitoring, contactless temperature measurement, oral and throat examinations, and assessment of skin conditions and lesions. Its value lies in enabling doctors to access real-time clinical data during consultations and combine it with historical patient data for more personalized diagnostic and treatment decisions. This is especially relevant for chronic disease follow-up and populations that require continuous monitoring.
The official website does not disclose plans, pricing, purchasing methods, free trials, or payment options. It also does not state whether pricing is based on devices, physician seats, institutional subscriptions, or service volume. On third-party integrations, the available text does not mention support for electronic medical records, hospital information systems, video conferencing systems, payment platforms, or insurance platforms; API and developer capabilities are also not publicly documented. On compliance, the page mentions “Trusted Regulatory Approval” and says the device meets the standards of leading health regulatory authorities, but it does not list specific certifications, applicable countries, approval numbers, or data security measures. Medical institutions should therefore carefully verify certifications, privacy compliance, and data processing agreements before procurement.
The main advantage is a clear product direction: upgrading remote consultations from “video communication” to “remote clinical examinations that can collect vital signs.” The feature coverage is broad, and the product emphasizes real-time data, chronic disease monitoring, and data-driven decision-making. The downside is that the official website still feels like an early-stage showcase and lacks the pricing, deployment, permission management, integration, API, support, and compliance details that SaaS enterprise buyers care about most. It is better suited for telehealth service providers, clinics, chronic disease management organizations, family doctor service teams, and medical institutions looking to improve the quality of remote consultations.
Availability of access, payments, and services in mainland China cannot be determined from the available text, so china_access is marked as unknown. Given that medical devices and telehealth in China involve local registration, data compliance, physician licensing, and internet hospital qualifications, local market access should be carefully verified before use in China. Comparable options include Teladoc Health, Amwell, TytoCare, as well as domestic internet hospitals, chronic disease management platforms, and remote medical hardware solutions.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on ombumed.com official site.
ombumed.com is an Unknown SaaS Tools provider. TG4G tracks its product information, an overall rating of 5.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach ombumed.com directly.